[1] Chen CJ, Yang HI, Su J, et al, for the REVEAL-HBV Study group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006,295:65-73.
[2] Terrault NA, Bzowej NH, Chang KM, et al. American Association for the Study of Liver Diseases. AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology, 2016,63:261-283.
[3] Zoutendijk R, Reijnders JGP, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of nave patients with a partial virologic response. Hepatology,2011,54:443-451.
[4] Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017,66:335-343.
[5] Kim HS, Kim BK, Kim SU, et al. Clinical outcomes were comparable between chronic hepatitis B patients with virological response using oral antiviral therapy and inactive carriers when adjusting for fibrotic burden. Hepatology, 2016,64(Suppl. S1):38A. |
